New Data Shows CAPLYTA® May Help Adults with MDD Achieve Remission Johnson & Johnson today announced a new analysis of Phase 3 data which found CAPLYTA® (lumateperone), in combination with an antidepressant, showed significantly greater remission rates in adults with major depressive…
Johnson & Johnson Launches Mobile Simulator App to Empower Breast Augmentation Patients Johnson & Johnson announced the U.S. launch of the Arbrea Breast Simulator Surgeon App for Mentor, a digital consultation tool available on tablets and smart phones that helps plastic…
Legend Biotech Showcases Latest Business Developments at 44th Annual J.P. Morgan Healthcare Conference Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today provided an update on the Company’s recent commercial and clinical progress and outlined its…
WuXi Biologics Secures UK MHRA GMP Certification for Commercial Production of Ophthalmic Biologic WuXi Biologics a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi –Drug Product Facility 5 (DP5) and…
Royalty Pharma to Showcase Achievements and Share Business Update at J.P. Morgan Healthcare Conference Royalty Pharma plc today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the…
Biogen Secures European Commission Approval for High-Dose SPINRAZA® (nusinersen) Regimen in Spinal Muscular Atrophy Biogen Inc. today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL…
BCG and Hippocratic AI Announce Strategic Collaboration to Deploy Agentic AI Across Biopharma and Medtech Boston Consulting Group (BCG) and Hippocratic AI today announced a global collaboration aimed at transforming the biopharma and medtech industries through the responsible implementation of…
At JPM26, Policy and Politics Will Loom Large for Pharma as Biotech Sees the Sun Heading into the J.P. Morgan Healthcare Conference for the past few years, industry watchers have tried to will deals into existence with effusive optimism despite…
The agreement aims to improve medicine affordability while supporting U.S.-based manufacturing and pharmaceutical innovation. Johnson & Johnson healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs…
Phase 2 studies advance following encouraging clinical data for T-cell engagers in autoimmune diseases Candid Therapeutics, Inc. a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced continued clinical progress with…
Collaboration focuses on advancing cell-specific siRNA therapies for cardiovascular disease treatment. Bayer and Soufflé Therapeutics™, an innovative biotech company that discovers and develops cell-selective genetic therapies, today announced a strategic collaboration and global licensing agreement to advance a heart-targeted small…
Regulatory milestone strengthens 4Moving Biotech’s leadership in osteoarthritis drug innovation 4Moving Biotech, a clinical-stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)…
